Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Inventory (2019 - 2025)

Historic Change in Inventory for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to $9.1 million.

  • Catalyst Pharmaceuticals' Change in Inventory rose 35366.95% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 2357.49%. This contributed to the annual value of $3.9 million for FY2024, which is 1776.75% down from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Change in Inventory is $9.1 million, which was up 35366.95% from -$455000.0 recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Change in Inventory high stood at $9.1 million for Q3 2025, and its period low was -$1.9 million during Q2 2024.
  • For the 5-year period, Catalyst Pharmaceuticals' Change in Inventory averaged around $1.0 million, with its median value being -$43000.0 (2022).
  • The largest annual percentage gain for Catalyst Pharmaceuticals' Change in Inventory in the last 5 years was 212110.09% (2023), contrasted with its biggest fall of 124186.05% (2023).
  • Over the past 5 years, Catalyst Pharmaceuticals' Change in Inventory (Quarter) stood at $920000.0 in 2021, then tumbled by 135.54% to -$327000.0 in 2022, then skyrocketed by 2121.1% to $6.6 million in 2023, then crashed by 107.2% to -$476000.0 in 2024, then soared by 2009.03% to $9.1 million in 2025.
  • Its Change in Inventory stands at $9.1 million for Q3 2025, versus -$455000.0 for Q2 2025 and $237000.0 for Q1 2025.